Robert Schlossman

Author PubWeight™ 59.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012 6.24
2 The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2002 3.73
3 Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2002 3.62
4 Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002 2.66
5 Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003 1.92
6 Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2012 1.91
7 Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005 1.89
8 New drugs for myeloma. Oncologist 2007 1.84
9 Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005 1.84
10 Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011 1.66
11 Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2006 1.63
12 Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006 1.62
13 Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009 1.54
14 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003 1.53
15 Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004 1.43
16 Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005 1.42
17 Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008 1.36
18 Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 2005 1.24
19 Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2002 1.15
20 Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 2011 1.14
21 The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2003 1.12
22 Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res 2007 1.04
23 Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 2002 1.02
24 The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program 2007 1.02
25 Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 2004 1.01
26 Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs 2007 0.95
27 CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991) 2001 0.94
28 New treatments for multiple myeloma. Oncology (Williston Park) 2005 0.94
29 Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. J Immunother (1991) 2001 0.91
30 Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res 2003 0.90
31 Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park) 2007 0.89
32 Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid 2010 0.89
33 Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol 2011 0.85
34 Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol 2011 0.82
35 Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008 0.81
36 Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Semin Oncol 2003 0.81
37 Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood 2004 0.81
38 Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion 2004 0.80
39 Emerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma 2005 0.78
40 Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol 2014 0.78
41 The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis 2010 0.78
42 Bortezomib in the management of multiple myeloma. Cancer Manag Res 2009 0.77
43 Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol 2012 0.76
44 Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc 2010 0.75